Q2 FY2026 · ended Jun 30, 2026 · Revenue $166,131, +2.0% YoY · Filed Aug 13, 2026
Co-Diagnostics, Inc. (CODX) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $166,131 and a net loss of $6.3 million. Free cash flow was -$7.2 million. As of Jun 30, 2026 it held $3.6 million in cash and investments and $1.8 million in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- CODX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- UT
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1692415
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $166,131 | $145,954 | $263,922 | $145,380 | $162,910 |
| Operating income | -$6.2M | -$9.2M | -$26.5M | -$7.0M | -$8.1M |
| Net income | -$6.3M | -$9.1M | -$25.7M | -$5.9M | -$7.7M |
| Diluted EPS | -$1.46 | -$4.06 | $0.27 | -$0.16 | -$7.00 |
| Operating cash flow | -$7.2M | -$7.8M | -$6.2M | -$5.9M | -$8.3M |
| Free cash flow | -$7.2M | -$8.0M | -$6.3M | -$6.0M | -$8.7M |
| Total assets | $16.6M | $21.5M | $24.7M | $44.7M | $46.5M |
| Total liabilities | $3.9M | $5.5M | $4.1M | $4.9M | $5.3M |
| Stockholders' equity | $12.7M | $16.0M | $20.6M | $39.8M | $40.7M |
| Cash and investments | $3.6M | $8.2M | $11.9M | $11.4M | $13.4M |
| Total debt | $1.8M | $2.0M | $1.2M | $1.5M | $1.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 15, 2026 | Oct 14, 2026 |
| 8-K/A |
Amended current report
Material agreement, New debt, Unregistered share sale
|
Oct 15, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Oct 13, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 25, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 16, 2026 | Sep 16, 2026 |
All 390 Co-Diagnostics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.